 Immunovant is developing a similar drug to argenx, but at 10 of argenxs valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin levels which was the key overhang for batoclimab. 